Skip to content

Commit

Permalink
paper: DOI
Browse files Browse the repository at this point in the history
  • Loading branch information
jhrcook committed Feb 15, 2021
1 parent cbad559 commit a249658
Show file tree
Hide file tree
Showing 4 changed files with 2 additions and 0 deletions.
2 changes: 2 additions & 0 deletions README.md
Original file line number Diff line number Diff line change
Expand Up @@ -6,6 +6,8 @@ Doga C. Gulhan <a href="https://orcid.org/0000-0001-5419-0549"><img src="https:/
Peter J. Park <a href="http://orcid.org/0000-0001-9378-960X"><img src="https://orcid.org/sites/default/files/images/orcid_16x16.png" style="width:1em;margin-right:.5em;" alt="ORCID iD icon"></a>,
Kevin M. Haigis <a href="https://orcid.org/0000-0003-1922-4509"><img src="https://orcid.org/sites/default/files/images/orcid_16x16.png" style="width:1em;margin-right:.5em;" alt="ORCID iD icon"></a>

[![DOI](https://zenodo.org/badge/DOI/10.5281/zenodo.4542077.svg)](https://doi.org/10.5281/zenodo.4542077)

## Abstract

Mutational activation of *KRAS* promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations. Although epidemiological studies connect specific alleles to clinical outcomes, the mechanisms underlying the distinct clinical characteristics of mutant *KRAS* alleles are unclear. Here, we analyze 13,492 samples from these four tumor types to examine allele- and tissue-specific genetic properties associated with oncogenic *KRAS* mutations. The prevalence of known mutagenic mechanisms partially explains the observed spectrum of *KRAS* activating mutations. However, there was are substantial differences between the observed and predicted frequencies for many alleles, suggesting that biological selection underlies the tissue-specific frequencies of mutant alleles. Consistent with experimental studies that have identified distinct signaling properties associated with each mutant form of K-RAS, our genetic analysis reveals that each *KRAS* allele is associated with a distinct tissue-specific comutation network. Moreover, we identify tissue-specific genetic dependencies associated with specific mutant *KRAS* alleles. Overall, this analysis demonstrates that the genetic interactions associated with oncogenic *KRAS* mutations are allele- and tissue-specific, underscoring the complexity that drives their clinical consequences.
Expand Down
Binary file modified paper/submission/03/FINAL/Cook_clean-version.docx
Binary file not shown.
Binary file modified paper/submission/03/FINAL/Cook_mark-up.docx
Binary file not shown.
Binary file modified paper/submission/03/comutation-manuscript_3.docx
Binary file not shown.

0 comments on commit a249658

Please sign in to comment.